Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 4/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095989 | 0.83 | NR1H4 (0.46) | NR1H4GABRB3NPBWR1MCHR1KCNJ5 | |
| SCHEMBL2773215 | 0.80 | GABRA1 (0.39) | NR1H4GABRB3GABRA1GABRG2MAPK14 | |
| SCHEMBL19689518 | 0.74 | NR1H4 (0.47) | NR1H4GABRB3GABRA2GABRB2MAPK1 | |
| SCHEMBL2770326 | 0.74 | CYP11B1 (0.39) | NR1H4GABRB3GABRA2GABRB2MAPK1 | |
| SCHEMBL2773022 | 0.73 | GABRA1 (0.33) | GABRB3GABRA1GABRG2 | |
| SCHEMBL2772785 | 0.70 | CCR1 (0.34) | NR1H4GABRB3GABRA1GABRG2P2RX7 | |
| SCHEMBL2774647 | 0.70 | NR1H4 (0.45) | NR1H4NPBWR1MCHR1MAPK14 | |
| SCHEMBL1096331 | 0.69 | NR1H4 (0.44) | NR1H4NPBWR1MCHR1MAPK14 | |
| SCHEMBL22380324 | 0.67 | GABRA1 (0.42) | GABRB3GABRA1GABRG2 | |
| SCHEMBL21340190 | 0.67 | NR1H4 (0.43) | NR1H4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR1H4 1/4885GABRB3 405/4885GABRA2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.